Partners with leading growth strategy firm,
Fletcher Spaght
Tivic Health® Systems, Inc. (“Tivic Health”, Nasdaq: TIVC), a
health tech company that develops and commercializes bioelectronic
medicine, today announced it has partnered with Fletcher Spaght
(“FSI”), a leading healthcare growth strategy firm, to accelerate
development of its commercial strategy for non-invasive cervical
vagus nerve stimulation (“ncVNS”).
Polaris Market Research estimates the global vagus nerve
stimulation market will grow from $8.59 billion in 2021 to $21.3
billion in 2030, a 10.6% CAGR over the forecast period.
Additionally, IDTechEx has forecast peripheral nerve stimulation,
the segment targeted by Tivic Health, will grow at 35% CAGR, one of
the fastest growth segments in bioelectronic medicine.
FSI Partner, Bill Sigona, stated, “FSI excels at projects like
this, where our insights help clients like Tivic grow while
improving patient healthcare. Bringing innovative technologies like
ncVNS to market drives us, and we're excited to support Tivic's
journey in advancing care across multiple therapeutic areas.”
The firm has begun a comprehensive market assessment of Tivic
Health’s ncVNS technology drawing from clinical outcomes from Tivic
Health’s Phase 1 trial. Fletcher Spaght initially identified
approximately 30 potential medical use cases for Tivic Health’s
ncVNS technology in neurologic, cardiac, psychiatric and autonomic
nervous system diseases. The firm is now working closely with Tivic
Health’s scientific and clinical leadership to identify the
strongest market entry point by interviewing clinical key opinion
leaders, patients and payers.
“The work with Fletcher Spaght will help us sharpen our
go-to-market strategy, clinical study plans, reimbursement pathway,
and product development pipeline for our vagus nerve stimulation
program,” explained Jennifer Ernst, CEO of Tivic Health. “The early
outcomes from the engagement confirm there are significant market
opportunities for our novel non-invasive bioelectronic
therapies.”
Tivic Health has previously announced the successful completion
of a Phase 1 trial, in which the company’s ncVNS produced strong
physiological effects in neurological, cardiac, and autonomic
systems. Tivic Health engaged Fletcher Spaght to help evaluate and
prioritize clinical use cases for Tivic’s ncVNS platform. The
company expects to derive insights that will drive the company’s
clinical strategy and product development in 2025 and beyond.
About Tivic Health
Tivic Health is a commercial health tech company advancing the
field of bioelectronic medicine. Tivic Health’s technology
platforms leverage stimulation of the trigeminal, sympathetic, and
vagus nerve structures. Tivic Health’s non-invasive and targeted
approach to the treatment of inflammatory chronic health conditions
gives consumers and providers drug-free therapeutic solutions with
high safety profiles, low risk, and broad applications. Tivic
Health’s first commercial product ClearUP is an FDA approved,
award-winning, handheld bioelectronic sinus device. ClearUP is
clinically proven, doctor-recommended, and is available through
online retailers and commercial distributors. For more information
visit http://tivichealth.com @TivicHealth
About Fletcher Spaght
Fletcher Spaght (FSI) has a 40-year history of professional
excellence. Renowned for its analytical rigor and operational
expertise, FSI crafts effective growth strategies for a wide range
of clients, including major healthcare corporations, private equity
firms, and innovative startups. With thousands of successful
engagements, FSI has played a key role in launching numerous
companies, facilitating hundreds of strategic transactions, and
managing over $130 million in venture capital investments.
Forward-Looking Statements
This press release may contain “forward-looking statements” that
are subject to substantial risks and uncertainties. All statements,
other than statements of historical fact, contained in this press
release are forward-looking statements. Forward-looking statements
contained in this press release may be identified by the use of
words such as “anticipate,” “believe,” “contemplate,” “could,”
“estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,”
“potential,” “predict,” “project,” “target,” “aim,” “should,”
“will” “would,” or the negative of these words or other similar
expressions, although not all forward-looking statements contain
these words. Forward-looking statements are based on Tivic Health
Systems, Inc.’s current expectations and are subject to inherent
uncertainties, risks, and assumptions that are difficult to
predict. Further, certain forward-looking statements are based on
assumptions as to future events that may not prove to be accurate,
including as a result of changes to the company’s relationship with
Fletcher Spaght, changes to the company’s business strategy,
clinical trial results, consummation of any strategic transactions,
and the company’s need for, and ability to secure when needed,
additional working capital. Actual results could differ materially
from those contained in any forward-looking statement as a result
of various factors. Accordingly, you are cautioned not to place
undue reliance on such forward-looking statements. For a discussion
of risks and uncertainties relevant to the company, and other
important factors, see Tivic Health’s filings with the SEC,
including, its Annual Report on Form 10-K for the year ended
December 31, 2023, filed with the SEC on March 29, 2024, under the
heading “Risk Factors”; as well as the company’s subsequent filings
with the SEC. Forward-looking statements contained in this press
release are made as of this date, and Tivic Health Systems, Inc.
undertakes no duty to update such information except as required by
applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240917322098/en/
Media Contact: Morgan Luke
Morgan.Luke@tivichealth.com
Investor Contact: Hanover International, Inc.
ir@tivichealth.com
Grafico Azioni Tivic Health Systems (NASDAQ:TIVC)
Storico
Da Dic 2024 a Gen 2025
Grafico Azioni Tivic Health Systems (NASDAQ:TIVC)
Storico
Da Gen 2024 a Gen 2025
